US 11826321
Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
granted A61KA61K31/135A61K45/06
Quick answer
US patent 11826321 (Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions) held by TONIX PHARMA LIMITED expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TONIX PHARMA LIMITED
- Grant date
- Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/135, A61K45/06, A61K9/0056, A61K9/006